501 Ventures, LLC is a Life Science Accelerator that helps infuse science with development and commercialization expertise. 


We provide a turn key solution for innovation that is looking to progress. Our team manages 3-5 independent programs simultaneously and outsources minimal work, providing efficiency of all resources- financial, time, and talent. 


Typical programs are:

  • Small molecule assets that are being developed for non-oncology uses
  • Currently reviewing assets that are <2 years to the clinic through Phase 2
  • Funding requirements for current stage typically range from $5M -$15M


 We are currently reviewing clinical stage assets that are in need of funding and a management team.   Please contact info@501ventures.com

Management Team

Meg Powell, PharmD; Founder and Chief Executive Officer

Hazar Granko, PhD; VP of Drug Development and Regulatory Affairs

Meg Powell, PharmD; Founder and Chief Executive Officer

TARGET PharmaSolutions, Aerial Bio, GlaxoSmithKline, Eli Lilly, McKinsey


LinkedIn profile

Dave Brown; Chief Strategy Officer

Hazar Granko, PhD; VP of Drug Development and Regulatory Affairs

Meg Powell, PharmD; Founder and Chief Executive Officer

GlaxoSmithKline, Eli Lilly, ZS Associates


LinkedIn profile

Hazar Granko, PhD; VP of Drug Development and Regulatory Affairs

Hazar Granko, PhD; VP of Drug Development and Regulatory Affairs

Hazar Granko, PhD; VP of Drug Development and Regulatory Affairs

Emergo Bio, Kowa Research Institute, Impact Pharmaceutical Services, Lineberry Research Associates (CRO)


LinkedIn profile

Board of Advisors

Moise A Khayrallah, Ph.D.

Moise A Khayrallah, Ph.D.

Moise A Khayrallah, Ph.D.

Emergo Bio, Aerial Bio, Neuronex, Addrenex, GlaxoWellcome, Cytran, and Lineberry Research Associates (CRO)

Sue Mahony, Ph.D.

Moise A Khayrallah, Ph.D.

Moise A Khayrallah, Ph.D.

Eli Lilly, BMS, Amgen

Paul Sekhri

Moise A Khayrallah, Ph.D.

Paul Sekhri

eGenesis, Lycera, TEVA, TPG